Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy

Gastroenterology Clinics of North America

Volumn 38, Issue 2, 2009, Pages 289-303

  Cryer, Byron ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Clopidogrel prasugrel; Gastrointestinal bleeding; Helicobacter pylori; Risk; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ESOMEPRAZOLE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; AGING; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; DYSPEPSIA; GASTRODUODENAL EROSION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MUCOSA; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; INTESTINE INJURY; ISCHEMIA; LOW DRUG DOSE; NONHUMAN; REVIEW; STOMACH MUCOSA LESION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASODILATATION;

ASPIRIN; GASTROINTESTINAL HEMORRHAGE; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 65549120155     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.03.005     Document Type: Review

References (63)

1. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
2. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
3. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 288 (2002) 2411-2420
4. Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 51 (2008) 210-247
5. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
6. Duffy B., and Bhatt D.L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?. Am J Cardiovasc Drugs 5 (2005) 307-318
7. Patrono C., Rodriguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
8. Cryer B., and Feldman M. Effects of very low doses of daily, long-term aspirin therapy on gastric, duodenal and rectal prostaglandins and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
9. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
10. Fort F.T., Lafolie P., Tóth E., et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. Scand J Gastroenterol 35 (2000) 464-469
11. Ibáñez L., Vidal X., Vendrell L., et al. Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 23 2 (2006) 235-242
12. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
13. Chan F.K.L., Ching J.Y.L., Hung L.C.T., et al. Clopidogrel versus aspirin and esomeprazole for the prevention of recurrent ulcer bleeding. N Engl J Med 352 3 (2005) 238-244
14. Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 352 3 (2005) 287-289
15. Ma L., Elliott S.N., Cirino G., et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 98 11 (2001) 6470-6475
16. Kabbinovar F., Hurwitz H.I., Fehrenbaacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LA alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
17. Sheikh R.A., Romano P.S., Prindiville T.P., et al. Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls. J Clin Gastroenterol 34 (2002) 529-532
18. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
19. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
20. Chan F.K. Long-term incidence of ulcer bleeding with low-dose aspirin after eradication of H pylori: A 4- year prospective cohort study. Gastroenterology 128 (2005) A133
21. Kahn R., Robertson R.M., Smith R., et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 118 5 (2008) 576-585
22. Hernandez-Diaz S., and Garcia Rodriguez L. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 4 (2006) 22
23. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007) 813-818
24. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 364 (2004) 331-337
25. Bhatt D.L., Fox K.A., HackeW, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
26. Hallas J., Dall M., Andries A., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 (2006) 726-728
27. Lanas A., and Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 23 (2007) 163-173
28. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
29. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103 10 (2008) 2465-2473
30. Lanas A., Yeomans N., and Junghard O. Svedberg on behalf of the ASTERIX Investigators. Risk factors for gastroduodenal ulcer during treatment with acetylsalicylic acid for cardiovascular risk management. European Heart Journal 29 suppl 1 (2008) 402
31. Lanas A., Fuentes J., Benito R., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
32. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
33. de Abajo F.J., and Garcia Rodriguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 1 (2001) 1
34. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
35. Sørensen H.T., Mellemkjaer L., Blot W.J., et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95 9 (2000 Sep) 2218-2224
36. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
37. Collins R., MacMahon S., Flather M., et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 313 (1996) 652-659
38. Andreotti F., Testa L., Biondi-Zoccai G.G., et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27 (2006) 519-526
39. Ng F.H., Wong S.Y., Chang C.M., et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 18 (2003) 443-449
40. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
41. Khurram Z., Chou E., Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 18 (2006) 162-164
42. Bhatt D.L., Scheiman J., Abraham N.S., et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52 18 (2008) 1502-1517
43. Chey W.D., and Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102 (2007) 1808-1825
44. Donnelly M.T., Goddard A.F., Filipowicz B., et al. Low-dose misoprostol for the prevention of low-dose aspirin induced gastroduodenal injury. Aliment Pharmacol Ther 14 (2000) 529-534
45. Watanabe T., Sugimori S., Kameda N., et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 6 11 (2008) 1279-1282
46. Goldstein J.L., Huang B., Amer F., et al. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 26 (2004) 1637-1643
47. Fiorucci S., Santucci L., Gresele P., et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124 (2003) 600-607
48. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
49. Lanas A., Garci{dotless}a-Rodri{dotless}guez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
50. Cryer B., Lapuerta P., Jernamo, et al. Omeprazole can prevent the gastroduodenal mucosal injury associated with combined use of clopidogrel and aspirin. Am J Gastroenterol 103 Suppl 1 (2008) S49
51. Sung J., Lau J., Ching J., et al. Can aspirin be reintroduced with PPI inhibitor INFUSION after endoscopic hemostasis: a double-blinded randomized controlled trial. Gastroenterology 130 (2008) A44
52. Eisen G.M., Baron T.H., Dominitz J.A., et al. Guidelines on the management of anticoagulation and anti-platelet therapy for endoscopic procedures. Gastrointest Endosc 55 (2002) 775-779
53. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
54. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 10.1016/S0140-6736(08)61845-0
55. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
56. Li X.Q., Andersson T.B., Ahlstrom M., et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 821-827
57. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
58. Small D.S., Farid N.A., Payne C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48 (2008) 475-484
59. Siller-Matula J.M., Spiel A.O., Lang I.M., et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 (2009) 148 e1-5
60. Pezalla E., Day D., and Pulliadath A. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 52 12 (2008) 1038-1039
61. Aubert R.E., Epstein R.S., Teagarden J.R., et al. Understanding variability in antiplatelet drug effects in acute coronary syndromes. Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. Circulation 118 (2008) S815
62. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). Available at:. http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm Accessed January 20, 2009
63. PPI interactions with clopidogrel. The Medical Letter Inc 51 1303 (2009) 1-3